Acadian Asset Management LLC Has $739,000 Stake in Emergent BioSolutions Inc. (NYSE:EBS)

Acadian Asset Management LLC increased its holdings in shares of Emergent BioSolutions Inc. (NYSE:EBS) by 267.5% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 108,566 shares of the biopharmaceutical company’s stock after buying an additional 79,028 shares during the period. Acadian Asset Management LLC owned 0.21% of Emergent BioSolutions worth $739,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of the business. Susquehanna Fundamental Investments LLC acquired a new stake in shares of Emergent BioSolutions during the first quarter worth $300,000. BNP Paribas Financial Markets increased its stake in shares of Emergent BioSolutions by 155.3% in the 1st quarter. BNP Paribas Financial Markets now owns 163,589 shares of the biopharmaceutical company’s stock valued at $414,000 after acquiring an additional 99,520 shares during the last quarter. Charles Schwab Investment Management Inc. raised its position in shares of Emergent BioSolutions by 84.1% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 2,873,984 shares of the biopharmaceutical company’s stock valued at $6,898,000 after acquiring an additional 1,312,934 shares during the period. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Emergent BioSolutions in the 1st quarter valued at approximately $57,000. Finally, Vanguard Group Inc. boosted its stake in Emergent BioSolutions by 14.7% during the 1st quarter. Vanguard Group Inc. now owns 3,411,549 shares of the biopharmaceutical company’s stock worth $8,631,000 after acquiring an additional 436,911 shares during the last quarter. 78.40% of the stock is currently owned by institutional investors and hedge funds.

Emergent BioSolutions Stock Performance

Shares of EBS stock opened at $6.88 on Wednesday. The company has a debt-to-equity ratio of 1.16, a quick ratio of 0.54 and a current ratio of 1.06. Emergent BioSolutions Inc. has a 52 week low of $1.42 and a 52 week high of $15.10. The company’s 50 day moving average price is $9.63 and its two-hundred day moving average price is $6.13. The company has a market capitalization of $360.53 million, a P/E ratio of -0.62 and a beta of 1.60.

Emergent BioSolutions (NYSE:EBS) last posted its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported ($2.32) EPS for the quarter, missing the consensus estimate of ($0.97) by ($1.35). The company had revenue of $254.70 million during the quarter, compared to the consensus estimate of $199.47 million. Emergent BioSolutions had a negative net margin of 53.26% and a negative return on equity of 34.38%. During the same period in the prior year, the firm posted ($1.06) earnings per share. On average, analysts expect that Emergent BioSolutions Inc. will post -1.98 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the stock. Benchmark reiterated a “buy” rating and issued a $8.00 target price on shares of Emergent BioSolutions in a report on Friday, August 16th. Rodman & Renshaw reaffirmed a “buy” rating and set a $16.00 price objective on shares of Emergent BioSolutions in a research note on Friday, September 13th.

Emergent BioSolutions Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.